Press coverage about InVitae (NYSE:NVTA) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. InVitae earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 46.35691587684 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Shares of NVTA opened at $13.95 on Monday. InVitae has a 12 month low of $4.35 and a 12 month high of $15.48. The firm has a market cap of $963.22 million, a P/E ratio of -5.26 and a beta of 1.76. The company has a quick ratio of 3.75, a current ratio of 3.75 and a debt-to-equity ratio of 0.42.

InVitae (NYSE:NVTA) last announced its earnings results on Tuesday, August 7th. The medical research company reported ($0.47) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.07. InVitae had a negative net margin of 125.03% and a negative return on equity of 111.27%. The business had revenue of $37.31 million during the quarter, compared to analysts’ expectations of $30.70 million. equities research analysts predict that InVitae will post -2.01 EPS for the current year.

Several research analysts recently commented on the stock. ValuEngine cut shares of InVitae from a “hold” rating to a “sell” rating in a report on Tuesday, June 26th. Zacks Investment Research cut shares of InVitae from a “buy” rating to a “hold” rating in a report on Saturday, August 11th. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $11.00.

InVitae Company Profile

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

See Also: What is a Tariff?

Insider Buying and Selling by Quarter for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with's FREE daily email newsletter.